Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from The E3 ubiquitin ligase RBCK1: Implications in the tumor immune microenvironment and antiangiogenic therapy of glioma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41418-020-00696-6
10.1038/s41418-020-00696-6 · External reference
Potential of E3 ubiquitin ligases in cancer immunity: opportunities and challenges
2021 · External reference
10.1038/s41392-020-00421-2
10.1038/s41392-020-00421-2 · External reference
10.1038/ncb1821
10.1038/ncb1821 · External reference
The multifaceted role of the E3 ubiquitin ligase HOIL-1: beyond linear ubiquitination
10.1111/imr.12307 · 2015 · External reference
10.1158/0008-5472.can-09-2674
10.1158/0008-5472.can-09-2674 · External reference
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma
10.1038/s41419-019-1488-2 · 2019 · External reference
Linear ubiquitin chains: enzymes mechanisms and biology
10.1098/rsob.170026 · 2017 · External reference
10.1038/nrm3836
10.1038/nrm3836 · External reference
10.1126/science.aao1710
10.1126/science.aao1710 · External reference
10.1038/nature23270
10.1038/nature23270 · External reference
10.1038/s41586-020-2746-2
10.1038/s41586-020-2746-2 · External reference
10.1016/j.immuni.2013.07.008
10.1016/j.immuni.2013.07.008 · External reference
10.1038/s41591-018-0014-x
10.1038/s41591-018-0014-x · External reference
10.1038/nrc.2017.51
10.1038/nrc.2017.51 · External reference
Glioma
10.1038/nrdp.2015.17 · 2015 · External reference
10.1016/j.canlet.2020.02.002
10.1016/j.canlet.2020.02.002 · External reference
10.1148/radiol.2017151930
10.1148/radiol.2017151930 · External reference
10.1016/j.immuni.2019.12.018
10.1016/j.immuni.2019.12.018 · External reference
10.1038/s41582-018-0025-8
10.1038/s41582-018-0025-8 · External reference
10.1093/nar/gkaa1020
10.1093/nar/gkaa1020 · External reference
10.1126/science.aar4060
10.1126/science.aar4060 · External reference
The clinical utility of tumor mutational burden in non-small cell lung cancer
10.21037/tlcr.2018.10.08 · 2018 · External reference
10.1016/j.ccell.2018.03.010
10.1016/j.ccell.2018.03.010 · External reference
10.1016/j.immuni.2018.03.023
10.1016/j.immuni.2018.03.023 · External reference
10.1038/ncomms3612
10.1038/ncomms3612 · External reference
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
10.7150/thno.53649 · 2021 · External reference
10.1016/j.immuni.2013.07.012
10.1016/j.immuni.2013.07.012 · External reference
10.1038/s41591-018-0136-1
10.1038/s41591-018-0136-1 · External reference
10.1038/s41467-021-21246-9
10.1038/s41467-021-21246-9 · External reference
10.1101/gr.240663.118
10.1101/gr.240663.118 · External reference
10.1038/ncomms4887
10.1038/ncomms4887 · External reference
CMAP decrement as a potential diagnostic marker for ALS
10.1111/ane.12510 · 2016 · External reference
10.1038/s41467-023-35871-z
10.1038/s41467-023-35871-z · External reference
10.1186/s13045-019-0738-1
10.1186/s13045-019-0738-1 · External reference
10.1056/nejmc1713444
10.1056/nejmc1713444 · External reference
10.1158/2159-8290.cd-20-0522
10.1158/2159-8290.cd-20-0522 · External reference
10.1038/s41588-018-0312-8
10.1038/s41588-018-0312-8 · External reference
10.1016/j.ccell.2015.03.001
10.1016/j.ccell.2015.03.001 · External reference
High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells natural killer cells and dendritic cells in breast carcinoma
10.1002/jso.23095 · 2012 · External reference
Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment
2018 · External reference
10.1016/j.cell.2019.06.024
10.1016/j.cell.2019.06.024 · External reference
10.1016/j.ccell.2021.05.002
10.1016/j.ccell.2021.05.002 · External reference
10.1002/glia.20850
10.1002/glia.20850 · External reference
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre open-label randomised controlled phase 2 trial
10.1016/s1470-2045(18)30675-2 · 2019 · External reference
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib
10.1093/neuonc/noaa156 · 2021 · External reference
10.1038/s41591-019-0349-y
10.1038/s41591-019-0349-y · External reference
Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: arm E of the NCI-COG pediatric MATCH trial
10.1200/jco.21.02840 · 2022 · External reference
Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901
10.1186/s12885-017-3107-x · 2017 · External reference
HOXA1 binds RBCK1/HOIL-1 and TRAF2 and modulates the TNF/NF-κB pathway in a transcription-independent manner
2016 · External reference
10.1016/j.molcel.2020.05.034
10.1016/j.molcel.2020.05.034 · External reference
The effect of molecular diagnostics on the treatment of glioma
10.1007/s11912-017-0585-6 · 2017 · External reference
